Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies-Reference-Cited by-同舟云学术

Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies

Published:2015-07-03 Issue:5 Volume:42 Page:607-613
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Estborn L.¹,Joelson S.¹

Affiliation:

1. Patient Safety; AstraZeneca R&D; Mölndal Sweden

Funder

AstraZeneca

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.13304/fullpdf

Reference26 articles.

1. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review;El-Serag;Gut,2014

2. Systematic review: the global incidence and prevalence of peptic ulcer disease;Sung;Aliment Pharmacol Ther,2009

3. Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults;McKeage;Drugs,2008

4. Safety of long-term PPI therapy;Reimer;Best Pract Res Clin Gastroenterol,2013

5. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs;Laheij;JAMA,2004

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proton pump inhibitors: Understanding the associated risks and benefits of long-term use;American Journal of Health-System Pharmacy;2023-01-11

2. Proton pump inhibitors: Assessment of side effects and application in COVID-19 infection;Timocki medicinski glasnik;2022

3. Focus on gastroesophageal reflux disease in patients with cystic fibrosis;World Journal of Gastroenterology;2020-11-07

4. Proton Pump Inhibitor Controversies;Laryngopharyngeal and Gastroesophageal Reflux;2020

5. Proton pump inhibitors, adverse events and increased risk of mortality;Expert Opinion on Drug Safety;2019-09-23